.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
QuintilesIMS
McKinsey
US Department of Justice
Chinese Patent Office
Cantor Fitzgerald
Julphar
Accenture
Boehringer Ingelheim

Generated: December 18, 2017

DrugPatentWatch Database Preview

Atomoxetine hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for atomoxetine hydrochloride and what is the scope of atomoxetine hydrochloride freedom to operate?

Atomoxetine hydrochloride
is the generic ingredient in two branded drugs marketed by Apotex Inc, Aurobindo Pharma Ltd, Glenmark Pharms Ltd, Teva Pharms Usa, Zydus Pharms Usa Inc, and Lilly, and is included in six NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are fourteen drug master file entries for atomoxetine hydrochloride. Fourteen suppliers are listed for this compound. There are seven tentative approvals for this compound.

Pharmacology for atomoxetine hydrochloride

Medical Subject Heading (MeSH) Categories for atomoxetine hydrochloride

Tentative approvals for ATOMOXETINE HYDROCHLORIDE

Applicant Application No. Strength Dosage Form
u► Subscribe10MGCAPSULE; ORAL
u► Subscribe100MGCAPSULE; ORAL
u► Subscribe80MGCAPSULE; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-007Feb 14, 2005ABRXYesNo► Subscribe► SubscribeY► Subscribe
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-002Nov 26, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
Glenmark Pharms LtdATOMOXETINE HYDROCHLORIDEatomoxetine hydrochlorideCAPSULE;ORAL079019-004May 30, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Glenmark Pharms LtdATOMOXETINE HYDROCHLORIDEatomoxetine hydrochlorideCAPSULE;ORAL079019-006May 30, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Zydus Pharms Usa IncATOMOXETINE HYDROCHLORIDEatomoxetine hydrochlorideCAPSULE;ORAL079017-002Sep 17, 2010DISCNNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma LtdATOMOXETINE HYDROCHLORIDEatomoxetine hydrochlorideCAPSULE;ORAL079016-003May 30, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Zydus Pharms Usa IncATOMOXETINE HYDROCHLORIDEatomoxetine hydrochlorideCAPSULE;ORAL079017-006Sep 17, 2010DISCNNoNo► Subscribe► Subscribe► Subscribe
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-008Feb 14, 2005ABRXYesNo► Subscribe► SubscribeY► Subscribe
Apotex IncATOMOXETINE HYDROCHLORIDEatomoxetine hydrochlorideCAPSULE;ORAL078983-003May 30, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Apotex IncATOMOXETINE HYDROCHLORIDEatomoxetine hydrochlorideCAPSULE;ORAL078983-004May 30, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: atomoxetine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-005Nov 26, 2002► Subscribe► Subscribe
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-001Nov 26, 2002► Subscribe► Subscribe
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-007Feb 14, 2005► Subscribe► Subscribe
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-006Nov 26, 2002► Subscribe► Subscribe
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-004Nov 26, 2002► Subscribe► Subscribe
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-003Nov 26, 2002► Subscribe► Subscribe
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-002Nov 26, 2002► Subscribe► Subscribe
LillySTRATTERAatomoxetine hydrochlorideCAPSULE;ORAL021411-008Feb 14, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Argus Health
Merck
Citi
Healthtrust
Novartis
Mallinckrodt
UBS
Fish and Richardson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot